Efficacy and safety of the cathepsin K inhibitor, ONO-5334, and alendronate on post-menopausal osteopenia or osteoporosis: 2-year results from ocean study

被引：0
|
作者：
Eastell, R. [1 ]
Nagase, S. [2 ]
Boonen, S. [3 ]
Spector, T. [4 ]
Small, M. [2 ]
Kuwayama, T. [2 ]
Sawyer, J. [5 ]
Deacon, S. [2 ]
机构：
[1] No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England
[2] Ono Pharma UK Ltd, Clin Dev, London, England
[3] Katholieke Univ Leuven, Leuven, Belgium
[4] Kings Coll London, London WC2R 2LS, England
[5] Prism Biodev Ltd, Nantwich, Cheshire, England
来源：
BONE | 2011年 / 48卷
关键词：
D O I：
10.1016/j.bone.2011.03.131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S92 / S93
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of intravenous ibandronate 6mg infused over 15 minutes: results from a 2-year study of breast cancer patients with metastatic bone disease
    Heras, P
    Hatzopoulos, A
    Mitsibounas, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S260 - S261
  • [42] Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: Analysis of results from a 2-year, open-label extension study
    Dwyer, P.
    Lheritier, K.
    Steel, M.
    NEUROUROLOGY AND URODYNAMICS, 2006, 25 (06) : 657 - 658
  • [43] Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
    Dreyling, Martin
    Santoro, Armando
    Mollica, Luigina
    Leppae, Sirpa
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Nagler, Arnon
    Dimou, Maria
    Demeter, Judit
    Oezcan, Muhit
    Kosinova, Marina
    Bouabdallah, Krimo
    Morschhauser, Franck
    Stevens, Don A.
    Trevarthen, David
    Munoz, Javier
    Rodrigues, Liana
    Hiemeyer, Florian
    Miriyala, Ashok
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Zinzani, Pier Luigi
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : 362 - 371
  • [44] Efficacy and safety of intravenous ibandronic acid 6 mg infused over 15 minutes: Results from a 2-year study of colorectal cancer patients with metastatic bone disease
    Heras, P.
    Hatzopoulos, A.
    Kritikos, K.
    Karagiannis, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Long-term efficacy and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheumatoid arthritis - Results from a 2-year study.
    Burmester, GR
    van de Porte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, M
    Schattenkircher, M
    Emery, P
    Beck, K
    Dressler, R
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S537 - S537
  • [46] A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: Results from the 3-month double-blind period
    Tyring, S
    Rosoph, L
    Toth, D
    Zitnik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P171 - P171
  • [47] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter P.
    Sieper, Joachim
    van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Chu, Alvina D.
    Song, In-Ho
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 26 - 26
  • [48] Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter
    Sieper, Joachim
    Van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Chu, Alvina D.
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1925 - 1928
  • [49] Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
    Baraliakos, Xenofon
    van der Heijde, Desiree
    Sieper, Joachim
    Inman, Robert Davies
    Kameda, Hideto
    Maksymowych, Walter Peter
    Lagunes-Galindo, Ivan
    Bu, Xianwei
    Wung, Peter
    Kato, Koji
    Shmagel, Anna
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [50] Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
    van Vollenhoven, Ronald
    Hahn, Bevra
    Tsokos, George
    Lipsky, Peter
    Gordon, Robert
    Fei, Kaiyin
    Lo, Kim Hung
    Chevrier, Marc
    Zuraw, Qing
    Berry, Pamela
    Karyekar, Chetan
    Rose, Shawn
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345